title: Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group.
abstract: Twenty-five patients with progressive or recurrent neuroblastoma were treated with single-agent ifosfamide. In 2 of 10 relapsing patients, an objective response was observed. If ifosfamide is administered in a dose of 3000 mg/m2 for 2 days every 3 weeks, a response can be expected in 8% of the cases.
authors.affiliation: Emma Kinderziekenhuis, The Netherlands Cancer Institute, Amsterdam.
authors.forename: J
authors.initials: J
authors.lastname: de Kraker
authors.forename: J
authors.initials: J
authors.lastname: Pritchard
authors.forename: O
authors.initials: O
authors.lastname: Hartmann
authors.forename: J
authors.initials: J
authors.lastname: Ninane
mesh_terms: D001855:Bone Marrow Diseases / Q000139:chemically induced; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006417:Hematuria / Q000139:chemically induced; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy* / Q000473:pathology; D010865:Pilot Projects; D001745:Urinary Bladder Diseases / Q000139:chemically induced
chemical_list: D007069:Ifosfamide